Biotech

All Articles

Ideaya bags possibility on Biocytogen bispecific ADC in $400M package

.Ideaya Biosciences is betting $400 thousand in biobucks that a bispecific antibody-drug conjugate (...

Takeda takes $140M loss on fallen short epilepsy medicine, boasts FDA manage

.We currently understand that Takeda is actually expecting to locate a road to the FDA for epilepsy ...

VBI Injections files for insolvency, looks for asset sale

.Immunology biotech VBI Vaccinations is actually diverting precariously near the defining moment, al...

Celldex anti-cKIT antibody decrease hives in one more phase 2 study

.It's challenging to muscle in on a space as competitive as immunology, but Celldex Therapies feels ...

Boehringer provides to $1.3 B for checkpoint inhibitor biotech

.Boehringer Ingelheim is actually offering up to $1.3 billion for Nerio Rehabs and also a preclinica...

Ventyx's last resort for inflammatory med sides in Crohn's breakdown

.Ventyx Biosciences' Crohn's illness medicine did not help people achieve remission in a period 2 tr...

Cognition's phase 2 radiate records blemish Alzheimer's prospect

.Knowledge Rehabs' phase 2 sparkle trial has taken several of the gloss off the Alzheimer's ailment ...

BMS centers bispecific months after submitting to operate phase 3 trial

.Bristol Myers Squibb has had a whiplash change of mind on its BCMA bispecific T-cell engager, halti...

Charles Baum consumes Terremoto as chief executive officer

.Charles Baum, M.D., Ph.D., who looked after Mirati Therapeutics' $ 5.8 billion purchase to Bristol ...

Asarina to close after attempts to companion Tourette's drug neglect

.After reaching out to more than 200 companies to partner a Tourette syndrome treatment that showed ...